Effects of Tislelizumab combined with Pemetrexed and Cisplatin in treatment of patients with stage Ⅳ non-small cell lung cancer
Objective:To observe effects of Tislelizumab combined with Pemetrexed and Cisplatin in treatment of patients with stage Ⅳ non-small cell lung cancer.Methods:A prospective study was conducted on 102 patients with stage Ⅳ non-small cell lung cancer admitted to this hospital from August 2020 to August 2023.According to the random number table method,they were divided into study group and control group,51 cases in each group.The control group was treated with Pemetrexed combined with Cisplatin,while the study group was treated with Tislelizumab injection on the basis of the control group.The objective remission rate,the serum tumor markers[vascular endothelial growth factor(VEGF),neuron-specific enolase(NSE),cytokeratin 21-1 fragment(CYFRA21-1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]levels,the T cell subsets indicators(CD3+,CD4+,CD8+)levels,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate of the study group was 96.08％,which was significantly higher than 84.31％of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum VEGF,NSE,CYFRA21-1,CA125,CEA and other serum tumor markers in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3+and CD4+in the two groups were lower than those before the treatment,but those in the study group were higher than those in the control group;the level of CD8+in the two groups was higher than that before the treatment,but that in the study group was lower than the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tislelizumab combined with Pemetrexed and Cisplatin in the treatment of the patients with stage Ⅳ non-small cell lung cancer can improve the objective response rate,improve the levels of T cell subsets,and reduce the levels of tumor markers.Moreover,it is superior to simple Pemetrexed and Cisplatin treatment.
万方数据
维普
